Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "Yellow Fever Vaccine Market Report 2024" report has been added to ResearchAndMarkets.com's offering.
The yellow fever vaccine market has experienced significant growth, projected to continue from $4.32 billion in 2023 to $5.56 billion in 2028 at a CAGR of 5.2%.
This impressive development reflects the increased focus on preventive healthcare measures and public health initiatives. Global immunization campaigns, advancements in vaccine technology, and the implementation of international health regulations have been instrumental in controlling the spread of infectious diseases and bolstering market growth.
A key driver for the market expansion is the rise in international travel, leading to heightened demand for vaccines for travel-related compliance and individual protection. Health guidelines and the requirement of vaccination for entry into certain regions have made the yellow fever vaccine essential for many travelers. Statistical reports indicate that global international tourist figures significantly increased from 960 million in 2022 to 1.286 billion in 2023, underscoring the vaccine's importance for global health security.
Innovation in Vaccine Development
Prominent entities in the vaccine market are focusing on advanced vaccine research and development. Innovations such as the T-cell adaptive booster vaccine aim to provide enhanced and sustained immunity, meeting the complexities of global vaccine demand. Key mergers and acquisitions have further augmented the potential for innovative delivery methods and vaccine technologies, bolstering market capabilities.
Geographic and Sector Insights
Regionally, North America remains the largest market for yellow fever vaccines, with Asia Pacific regions anticipated to be the fastest-growing over the forecast period. The yellow fever vaccine market, which consists of vaccine administration equipment and storage solutions, plays a pivotal role in the public health infrastructure across various geographies and clinical settings.
About the Yellow Fever Vaccine
The yellow fever vaccine is a live, attenuated viral preparation providing long-lasting, often lifelong immunity. Its presentations in powder and liquid forms cater to different application needs, including routine immunization and traveler vaccinations. This vaccine is an essential component in combating the spread of the yellow fever virus in endemic regions and is distributed through an array of healthcare facilities.
The surge in market growth underlines the global commitment to preventing yellow fever and the trust in the vaccine's effectiveness. The robust expansion of the vaccine market is a testament to the collaborative efforts of health organizations, governments, private sectors, and the vaccine industry to ensure public health and safety at both local and global levels.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 175 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value (USD) in 2024 | $4.54 Billion |
| Forecasted Market Value (USD) by 2028 | $5.56 Billion |
| Compound Annual Growth Rate | 5.2% |
| Regions Covered | Global |
For more information about this report visit https://www.researchandmarkets.com/r/tdxase
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
